<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>RedChip Upcoming Webinars</title>
    <link>https://www.redchip.com/webinar</link>
    <atom:link href="https://www.redchip.com/webinar/rss" rel="self" type="application/xml" />
    <description>Latest upcoming webinars from RedChip.</description>
    <language>en-us</language>
    <lastBuildDate>Wed, 16 Sep 2026 20:15:00 +0000</lastBuildDate>
    <ttl>15</ttl>
    <item>
      <title><![CDATA[Nexalin Technology]]></title>
      <link>https://www.redchip.com/webinar/NXL/87940596953</link>
      <guid isPermaLink="true">https://www.redchip.com/webinar/NXL/87940596953</guid>
      <pubDate>Mon, 03 Aug 2026 20:15:00 +0000</pubDate>
      <description><![CDATA[Nexalin designs and develops innovative neurostimulation products to uniquely help combat the ongoing global mental health epidemic. All of Nexalin’s products are believed to be non-invasive and undetectable to the human body and are developed to provide relief to those afflicted with mental health issues. Nexalin utilizes bioelectronic medical technology to treat mental health issues. Nexalin believes its neurostimulation medical devices can penetrate structures deep in the mid-brain that are associated with mental health disorders. Nexalin believes the deeper-penetrating waveform in its next-generation devices will generate enhanced patient response without any adverse side effects. The Nexalin Gen-2 15 milliamp neurostimulation device has been approved in China, Brazil, and Oman.]]></description>
    </item>
    <item>
      <title><![CDATA[Nord Precious Metals Mining]]></title>
      <link>https://www.redchip.com/webinar/NPMMF/88654167145</link>
      <guid isPermaLink="true">https://www.redchip.com/webinar/NPMMF/88654167145</guid>
      <pubDate>Thu, 06 Aug 2026 20:15:00 +0000</pubDate>
      <description><![CDATA[Nord Precious Metals is a Canadian silver-focused resource company advancing a district-scale portfolio of past-producing silver assets in Ontario's historic Cobalt-Gowganda mining region, one of the world's highest-grade primary silver camps. The Company controls the Castle Mine property, the high-grade Castle East silver discovery, the recently acquired Miller Lake-O'Brien assets, and the Gowganda silver tailings project, creating a consolidated land position across past-producing properties that have historically produced more than 57 million ounces of silver.]]></description>
    </item>
    <item>
      <title><![CDATA[Proactive Sustainable Bonds]]></title>
      <link>https://www.redchip.com/webinar/PSB/87073639134</link>
      <guid isPermaLink="true">https://www.redchip.com/webinar/PSB/87073639134</guid>
      <pubDate>Tue, 11 Aug 2026 20:15:00 +0000</pubDate>
      <description><![CDATA[Proactive Sustainable Bonds™ is a real estate-backed investment platform focused on the acquisition, renovation, stabilization, and operation of workforce and affordable housing assets across the United States, supported by third-party verification, independent due diligence, a multi-state portfolio, and a demonstrated track record of value creation and investor distributions.]]></description>
    </item>
    <item>
      <title><![CDATA[BioVie]]></title>
      <link>https://www.redchip.com/webinar/BIVI/82597296515</link>
      <guid isPermaLink="true">https://www.redchip.com/webinar/BIVI/82597296515</guid>
      <pubDate>Wed, 12 Aug 2026 20:15:00 +0000</pubDate>
      <description><![CDATA[BioVie Inc. (NASDAQ: BIVI) is a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders (Alzheimer's disease, Parkinson’s disease and long COVID) and advanced liver disease. In neurodegenerative disease, the Company’s lead drug candidate bezisterim inhibits the production of tumor necrosis factor alpha (TNF-α) to reduce neuroinflammation and insulin resistance – both of which are drivers of Alzheimer’s and Parkinson’s. Bezisterim is also being evaluated to treat the neurological symptoms associated with long COVID, which are associated with persistent systematic inflammation and neuroinflammation. In liver disease, the Company is actively exploring partnerships for a Phase 3 trial to evaluate BIV201 (continuous infusion terlipressin) to reduce further decompensation in participants with liver cirrhosis and ascites. BIV201 has the potential to become the first therapeutic for ascites, a condition with 50% mortality rate within 12 months.]]></description>
    </item>
    <item>
      <title><![CDATA[Comprehensive Healthcare Systems]]></title>
      <link>https://www.redchip.com/webinar/CMHSF/83544332568</link>
      <guid isPermaLink="true">https://www.redchip.com/webinar/CMHSF/83544332568</guid>
      <pubDate>Tue, 18 Aug 2026 20:15:00 +0000</pubDate>
      <description><![CDATA[Following a multi-year operational restructuring and the installation of seasoned professional management, Comprehensive Healthcare Systems has transformed from a legacy, underinvested operator into a scalable, high-margin technology company with strong revenue visibility and accelerating momentum.]]></description>
    </item>
    <item>
      <title><![CDATA[Beyond the Index: The Next Generation of ETF Investing  ]]></title>
      <link>https://www.redchip.com/webinar/redchip/89581551123</link>
      <guid isPermaLink="true">https://www.redchip.com/webinar/redchip/89581551123</guid>
      <pubDate>Wed, 19 Aug 2026 13:30:00 +0000</pubDate>
      <description><![CDATA[RedChip's virtual investor conference, Beyond the Index: The Next Generation of ETF Investing, delivers direct access to the investment professionals driving innovation across the rapidly evolving ETF landscape. Discover funds and strategies designed to provide exposure to income-generating assets, thematic opportunities, active management approaches, alternative investments, and specialized market segments.   Hear portfolio managers and ETF sponsors discuss their investment philosophies, portfolio construction methodologies, market outlooks, and competitive advantages, then engage with them directly through live Q&A.   Whether you're a retail investor seeking innovative ways to build and diversify your portfolio or a professional evaluating emerging investment strategies and market opportunities, this is your most focused, efficient path into the next generation of ETF investing. 
Register today to secure your place.]]></description>
    </item>
    <item>
      <title><![CDATA[Bimergen Energy]]></title>
      <link>https://www.redchip.com/webinar/BESS/86716005545</link>
      <guid isPermaLink="true">https://www.redchip.com/webinar/BESS/86716005545</guid>
      <pubDate>Thu, 20 Aug 2026 20:15:00 +0000</pubDate>
      <description><![CDATA[]]></description>
    </item>
    <item>
      <title><![CDATA[Virax Biolabs Group]]></title>
      <link>https://www.redchip.com/webinar/VRAX/86449600416</link>
      <guid isPermaLink="true">https://www.redchip.com/webinar/VRAX/86449600416</guid>
      <pubDate>Tue, 25 Aug 2026 20:15:00 +0000</pubDate>
      <description><![CDATA[]]></description>
    </item>
    <item>
      <title><![CDATA[Clinch Resources]]></title>
      <link>https://www.redchip.com/webinar/CLCH/86427547349</link>
      <guid isPermaLink="true">https://www.redchip.com/webinar/CLCH/86427547349</guid>
      <pubDate>Wed, 26 Aug 2026 20:15:00 +0000</pubDate>
      <description><![CDATA[]]></description>
    </item>
    <item>
      <title><![CDATA[TransCode Therapeutics (NASDAQ: RNAZ)]]></title>
      <link>https://www.redchip.com/webinar/RNAZ/81817787778</link>
      <guid isPermaLink="true">https://www.redchip.com/webinar/RNAZ/81817787778</guid>
      <pubDate>Wed, 16 Sep 2026 20:15:00 +0000</pubDate>
      <description><![CDATA[TransCode Therapeutics is a clinical-stage oncology company developing a differentiated portfolio of RNA therapeutics, cancer vaccines, and immuno-oncology therapies designed to address advanced and metastatic cancers. The Company's proprietary nanoparticle delivery platform is engineered to overcome one of the greatest challenges in RNA medicine—efficiently delivering therapeutics directly to tumors beyond the liver—potentially enabling more precise treatment of metastatic disease. TransCode's lead candidate, TTX-MC138, has demonstrated encouraging clinical safety, evidence of tumor-targeted delivery in humans, and promising early efficacy, while advancing into a Phase 2a trial targeting minimal residual disease in colorectal cancer. Supported by technology developed at Harvard Medical School and Massachusetts General Hospital, TransCode has built a diversified oncology pipeline with multiple clinical and preclinical programs, creating several opportunities for value creation through upcoming clinical milestones and potential strategic partnerships.]]></description>
    </item>
  </channel>
</rss>
